Compare Freeport-McMoRan Inc (FCX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Merck & Co., Inc. — how do they compare? Freeport-McMoRan Inc trades at $59.1 (market cap $87.65B), while Merck & Co., Inc. trades at $127.3 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 3.5× Freeport-McMoRan Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| FCX | MRK | |
|---|---|---|
Market Cap | $87.65B | $305.29B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $129.52 |
52-Week Low | $35.34 | $77.60 |
Enterprise Value | $94.31B | $348.71B |
Dividend Yield | 0.98% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freeport-McMoRan (FCX) trades at $61.97, up 3.33% with a bearish technical signal despite three consecutive quarterly earnings beats. The copper miner shows improving fundamentals with revenue growth to $25.92B and net income of $2.20B in 2025, supported by strong copper demand. Analyst consensus remains bullish with a $72.94 price target, though the stock faces technical resistance near $63-64 levels.
FCX presents a compelling value proposition with expanding profit margins and strategic positioning in the copper market, though investors face volatility risks from commodity price fluctuations and ongoing negative cash flow trends. The company's expansion pipeline and dividend payments provide additional shareholder value drivers.
Merck (MRK) trades at $120.80, down 2.6% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The company reported strong recent earnings beats and maintains solid profitability with a 73.91% gross margin and 13.59% net margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology pipeline, while institutional investors continue accumulating shares.
The outlook remains positive with analyst consensus at Buy (67.57%) and a $137.30 price target, suggesting 13.7% upside. Key risks include integration challenges from the Terns acquisition, competitive pressures in oncology, and potential regulatory headwinds. Strong cash flow generation ($16.47B operating cash flow in 2025) supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
